The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target
|
journal
|
November 2016 |
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation
|
journal
|
June 1997 |
Disruption of the Bcl6 Gene Results in an Impaired Germinal Center Formation
|
journal
|
August 1997 |
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
|
journal
|
May 2011 |
Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
|
journal
|
October 2012 |
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
|
journal
|
September 2011 |
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy
|
journal
|
March 2014 |
BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells
|
journal
|
July 2008 |
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL
|
journal
|
May 2009 |
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR
|
journal
|
June 2007 |
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells
|
journal
|
September 2005 |
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
|
journal
|
December 2004 |
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
|
journal
|
December 2010 |
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
|
journal
|
September 2007 |
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells
|
journal
|
November 2004 |
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
|
journal
|
April 2009 |
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
|
journal
|
April 2010 |
Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas
|
journal
|
May 2008 |
B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma
|
journal
|
January 2008 |
BCL-6 in the Pathogenesis of Non-Hodgkin's Lymphoma
|
journal
|
January 2000 |
A new functional domain of Bcl6 family that recruits histone deacetylases
|
journal
|
September 2001 |
The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT
|
journal
|
October 1998 |
BCoR, a novel corepressor involved in BCL-6 repression
|
journal
|
July 2000 |
Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain
|
journal
|
December 2003 |
Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer
|
journal
|
February 2008 |
New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes
|
journal
|
June 2013 |
Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms
|
journal
|
March 2013 |
Discovery of a novel B-cell lymphoma 6 (BCL6)–corepressor interaction inhibitor by utilizing structure-based drug design
|
journal
|
September 2017 |
Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach
|
journal
|
May 2017 |
Discovery of Pyrazolo[1,5- a ]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
|
journal
|
May 2017 |
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
|
journal
|
September 2017 |
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
|
journal
|
August 2016 |
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
|
journal
|
April 2010 |
Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry
|
journal
|
January 2012 |
Twenty years on: the impact of fragments on drug discovery
|
journal
|
July 2016 |
Computational Fragment-Based Binding Site Identification by Ligand Competitive Saturation
|
journal
|
July 2009 |
Mapping Functional Group Free Energy Patterns at Protein Occluded Sites: Nuclear Receptors and G-Protein Coupled Receptors
|
journal
|
February 2015 |
Inclusion of Multiple Fragment Types in the Site Identification by Ligand Competitive Saturation (SILCS) Approach
|
journal
|
November 2013 |
Automated Selection of Compounds with Physicochemical Properties To Maximize Bioavailability and Druglikeness
|
journal
|
December 2010 |
The role of ligand efficiency metrics in drug discovery
|
journal
|
January 2014 |
Quantitative NMR Studies of High Molecular Weight Proteins: Application to Domain Orientation and Ligand Binding in the 723 Residue Enzyme Malate Synthase G
|
journal
|
April 2003 |
Are Free Energy Calculations Useful in Practice? A Comparison with Rapid Scoring Functions for the p38 MAP Kinase Protein System †
|
journal
|
October 2001 |
[20] Processing of X-ray diffraction data collected in oscillation mode
|
book
|
January 1997 |
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
|
journal
|
May 1997 |
The CCP4 suite programs for protein crystallography
|
journal
|
September 1994 |
PHENIX: a comprehensive Python-based system for macromolecular structure solution
|
journal
|
January 2010 |
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
|
journal
|
May 2007 |
Automated and accurate deposition of structures solved by X-ray diffraction to the Protein Data Bank
|
journal
|
September 2004 |
GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation
|
journal
|
February 2008 |
All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins †
|
journal
|
April 1998 |
Simulation of activation free energies in molecular systems
|
journal
|
August 1996 |
CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields
|
journal
|
January 2009 |
Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations
|
journal
|
July 2012 |
Iminoguanidines as Allosteric Inhibitors of the Iron-Regulated Heme Oxygenase (HemO) of Pseudomonas aeruginosa
|
journal
|
July 2016 |